Finch Therapeutics Announces Positive Topline Results from Randomized Controlled Trial of CP101, an Oral Microbiome Drug, for the Prevention of Recurrent C. difficile Infection

CP101 met the primary efficacy endpoint with statistically significant improvement in the prevention of recurrent C. difficile infection over standard of care alone in a 206-patient trial CP101 was well-tolerated with no treatment-related serious adverse events CP101 is the first oral microbiome drug to meet its primary endpoint in a pivotal trial Finch announces the[…]